BioNTech SE at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Okay. I believe we are live right now. Good morning, everyone, and welcome to the 42nd Annual Goldman Sachs Global Healthcare Conference. My name is Chris Shibutani. I'm a member of the research team in the biotech group. Joined by my colleague, CJ Zopf, we're very pleased to kick off this year's conference with a presentation and discussion with BioNTech. Clearly one of the incredibly emerging stories from 2020, increasing relevant for global investors.
Joining us today, we have Ryan Richardson, Chief Strategic Officer and Managing Director. Ryan, thank you so much for joining us today.
Thank you, Chris. Good to be with you.
Before we kick off, I am required, apparently, to read a series of disclosures. So we'll see if we can get through this.
The
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |